Business
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Jefferies Global Healthcare ConferenceFormat: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New
About this update from Tvardi Therapeutics, Inc.
[{"type":"image","alt":"Tvardi Therapeutics","displaySize":"","headline":null,"caption":"Tvardi Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v11.qHOvz06m91J_zyDSiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a","width":300,"height":158},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/v11.qHOvz06m91J_zyDSiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a","width":300,"height":158}},"lazy":false},{"type":"text","content":"HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:","length":363,"tagName":"p"},{"type":"text","content":"Jefferies Global Healthcare ConferenceFormat: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New York, NY","length":149,"tagName":"p"},{"type":"text","content":"Raymond James BioPharma CEO Strategy SeriesFormat: Fireside ChatDate: Friday, June 5, 2026Time: 10:00 AM ETRegistration Link: Here","length":134,"tagName":"p"},{"type":"text","content":"The webcasts of the Jefferies and Raymond James fireside chats will be accessible on the Tvardi Investors’ website. A replay of the webcasts will be available for approximately 90 days following the conference.","length":210,"tagName":"p"},{"type":"text","content":"About Tvardi Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of c...